Local delivery of anticancer drug in tumor using miniaturized implants over a prolonged period of time is a powerful treatment strategy that provides lower toxicity and higher drug bioavailability compared to conventional systemic chemotherapy. Prediction of anticancer drug distribution in tumor following implantation of the drug implant is necessary to improve and optimize the implantable drug delivery systems (IDDSs). In this paper, we develop mathematical and stochastic simulation models for the prediction of spatiotemporal concentration of anticancer doxorubicin following implantation of a dualrelease implant in an isolated tumor microenvironment (TME). Our model utilizes mathematical convolution of the channel impulse response (CIR) with the drug release function based on the abstraction of molecular communication. The derived CIR can be used to obtain drug concentration profile in the surrounding tissue for various release profiles and different anticancer drugs. We derive closed-form analytical expression for anticancer drug concentration. The required release rates are obtained by fitting the experimental data on dual-release implant available in the literature to a mathematical expression. In addition, we also present a particle-based stochastic simulator and compare the results with those predicted by the analytical model. The accuracy of predictions by both the models is further verified by comparing with the published experimental data in the literature. Both the proposed models can be useful for the design optimization of the implantable drug delivery systems (IDDSs) in tumors and other tissues and can potentially reduce the number of animal experiments thus saving cost and time.
I. INTRODUCTION
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells [1] . Cancer can be treated using many treatment modalities, e.g., surgery, chemotherapy, etc. Although systemic drug delivery (conventional chemotherapy) is a preferred and widely used technique for anticancer drug administration, it suffers from poor drug bioavailability due to high elimination, enzymatic degradation, and other barriers as well as toxic side-effects due to accumulation in other healthy parts of the body [2] . Many alternative techniques of drug delivery for cancer treatment have already been introduced to overcome these limitations.
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Drug delivery from a miniaturized implant is one such technique which not only offers an efficient alternative but also can act as adjunctive therapy to other treatment techniques, particularly when the conventional therapies fail or can't be applied [3] . Also, the implantable drug delivery systems (IDDSs) have been found to offer lower toxicity and higher drug bioavailability compared to systemic chemotherapy [4] . In IDDS approach, the anticancer drug will be gradually delivered inside the tumor over a prolonged period of time, that may range from days to years without having to pass through the endothelial barrier of the tumor vasculature. In addition, the same implant could release a combination of different types of drugs. A polymeric membrane with controlled drug release was first proposed by Folkman and Long in 1964 who examined the use of silicone rubber VOLUME 7, 2019 This work is licensed under a Creative Commons Attribution 4.0 License. For more information, see http://creativecommons.org/licenses/by/4.0/ (Silastic R ) for prolonged systemic drug administration [5] . Later, degradable polymer implants such as Gliadel R polymer and poly (lactic-co-glycolic acid) (PLGA) polymer have been clinically approved [6] , [7] . Cancer cell death depends on the concentration of anticancer drug in its vicinity, where a minimum threshold level of drug concentration is required to destroy the cells. Drug concentration in tumor depends on the various biochemical and biophysical processes, such as drug release rate, diffusion properties of the environment, and drug elimination rate [8] . Knowledge of the spatiotemporal drug concentration profiles inside human tissues would be useful to design the IDDS and to minimize toxic levels at the healthy cells. Direct measurement of drug concentration in human tissues could be difficult and can't be readily obtained. Mathematical and stochastic models can be used to help understand and predict spatiotemporal drug distribution following insertion of drug implants in tumors. These models can be used together with both the animal experiments and clinical trials to improve the drug delivery system. Further, they may help to extend the in vivo results from animal models directly to humans thus offering a direct link between the laboratory experiments and clinical applications.
Most of the mathematical and simulation models for the transport and distribution of anticancer drugs in tumors are limited to systemic administration, i.e., via blood. A number of experimental studies have been reported on the measurement of drug concentration due to insertion of drug implants in tumors, e.g., [7] , [9] - [21] . However, only a few studies on mathematical modelling of drug distribution due to tumor implants exist in the literature. A finite-difference numerical (computational) model for drug distribution and elimination in the vicinity of a polymer implant was developed in [22] . Analytical expressions for the prediction of the drug concentration of Carmustine (BiCNU R ) in rat and monkey brain tissues were derived analytically in [23] - [25] . However, these models assume either a constant drug release pattern at the implant/tissue interface or use steady-state approximations. Numerical models for prediction of the transport parameters, e.g., diffusivity and elimination rate, following the release of doxorubicin (DOX) from dual-release polymer implant in liver tissues were proposed in [14] , [19] , [20] . In [26] , [27] , prediction of drug transport and clearance in the brain following drug release from polymers was obtained numerically using the finite-element method. The effect of various factors on the delivery of BCNU drug to brain tumors using polymers was examined using a computational finite-element model in [28] . A computational fluid dynamic model was developed for investigating the suitability of the transport of various chemotherapeutic drugs using polymeric wafers in brain tumor [29] . However, all these models use numerical methods to obtain solutions, thus lending themselves to many simplifying approximations that might reduce the accuracy of their prediction. Also, most of the reported models resort to unrealistic modelling of the release rate function; e.g., choosing either a constant or a simple decaying exponential function for the release rate. However, in most realistic drug implants, the drug release rate decreases with time after the insertion of the implant in the tissue. Thus, it is essential that the drug release models closely follow the release patterns revealed in the experimental investigations. In this paper, we propose novel analytical and stochastic simulation models for anticancer drug delivery into tumors using implantable drug delivery devices. Our models are aided by the abstraction offered by the molecular communication paradigm. The main contributions of this paper can be summarized as follows: (1) development of a new mathematical model for drug release and distribution of anticancer drug doxorubicin (DOX) following implantation of dualrelease drug-loaded implant in the tumor using the molecular communication (MC) paradigm coupled with the convolution approach. The convolution approach is more general than the classical compartmental modeling approach [30] . The anticancer drug (DOX) is chosen because it is widely used in chemotherapy due to its efficacy in destroying a wide range of cancers [31] . In the MC paradigm, the implant is abstracted as a transmitter while the target site, i.e., malignant cell, is treated as a molecular receiver, as shown in Fig. 1 . From the perspective of MC, DOX molecules represent the information molecules which are transported from the transmitter to the receiver. Here, the tumor microenvironment (TME) represents the propagation channel in which DOX molecules get randomly diffused from the transmitter to the receiver. (2) Another original contribution made in this paper is the modelling of the dynamics of drug release from the polymer implant as well as the distribution and elimination of drug molecules within the tumor tissue. (3) Development of convolution modelling by the derivation of a channel impulse response (CIR) to characterize the system components is another contribution of this paper. In contrast to other existing models, the analytical model proposed in this paper offers a more general approach for obtaining the spatiotemporal drug concentration profile to any drug release function of the implant based on the convolution with the derived CIR in the time domain. (4) We employ realistic drug release rate function to develop a closed-form analytical expression for anticancer drug concentration profile in the tumor. This is done by fitting a mathematical function to the published experimental release data of dual-release implant [7] . (5) A stochastic random walk diffusion simulation model is also proposed for tracking the random Brownian motion of the molecules. The development of this stochastic model is completely independent of the proposed analytical model. Hence the stochastic model can be used to validate the analytical model. To the best of our knowledge, no stochastic simulation models have been reported so far for the release and distribution of anticancer drug in tumors using IDDSs.
The proposed analytical and stochastic models can help to predict the spatiotemporal drug concentration levels in the tumor and the surrounding healthy tissues, which helps to optimize the design of the IDDSs. Further, these models can also potentially contribute to reducing the number of experimental (or clinical) trials and thus will save time and cost. The proposed models can also be generalized to include drug transport in other tissues and even for delivering different drug molecules just by incorporating the tissue and drugspecific characteristic parameters.
The remainder of this paper is organized as follows. The mathematical derivation of the CIR and the release kinetic model are presented in section II. Also, the spatiotemporal drug concentration profile in the tumor is obtained by applying the convolution integral between the CIR and the release rate function. In section III, we describe the development of the stochastic particle-based simulator for DOX drug distribution in the vicinity of the implant and the surrounding tissue. Results obtained by both the analytical and stochastic simulation models are presented in section IV. These results are also compared with the experimental data extracted from the published literature [19] . Finally, a discussion is presented in section V, where the key contributions are highlighted.
II. DEVELOPMENT OF ANALYTICAL MODEL
In this section, we derive the spatiotemporal concentration profile in tumor tissues analytically. This is done by convolving the implant release function with the derived channel impulse response (CIR). Here, the drug source is assumed to be a miniaturized spherical implant located inside a spherically shaped isolated tumor, as shown schematically in Fig. 1 . The implant is surrounded by biological tumor tissue, composed of cells and an extracellular space (ECS) filled with extracellular fluid (ECF). The implant is assumed to be loaded with anticancer drug doxorubicin (DOX) that is immediately released from the polymer into the vicinity of the implant after implantation. The released drug (DOX) will transport through the ECS (via diffusion and convection) and it may uptake by the cells through passive, active, or facilitated transport paths. Moreover, drugs could be eliminated into the systemic circulation via diffusion across the semipermeable membranes of capillaries. Also, drug molecules may be converted into other compounds due to various factors such as enzymes. Some molecules could bind to immobile elements in the surrounding tissue. All these processes could affect therapeutic efficacy.
Tumor tissues can be treated as porous media because the length scale of the intercapillary distances (i.e., the average distances between the capillaries) is much smaller than the length scale of the tumor radius [32] . Moreover, the tumor is assumed to be isolated from the surrounding healthy tissues [32] . We assume that the interstitial velocity field is very small and can be neglected throughout most parts of the tumor tissue. Therefore, drug transport in the interstitial space (porous medium) and drug elimination in tumor tissue are mathematically governed by the following diffusion equation:
where ∇ 2 is Laplacian operator, C is the spatiotemporal distribution (concentration) of drug molecules in tumor tissue, D is the diffusion coefficient of the drug in tumor tissue in the unit of (m 2 /s), γ is the first-order elimination rate constant of drug due to various elimination processes, and t is the time after implantation. When the binding/uptake process is much faster compared to the diffusion process, the local equilibrium between the free and bound molecules will be attained [33] . Therefore, the apparent diffusion coefficient (ADC) and the apparent first-order elimination rate constant can be expressed as follows, respectively, [20] , [22] 
where, D w and γ w is the drug diffusivity and lumped firstorder elimination rate constant without including the binding effect. The parameter k bind is the first-order binding constant of drug molecules with the target sites in the environment, e.g., cells, proteins, etc.
In the implantable drug delivery systems (IDDSs), the rapid elimination (perfusion) of drug molecules through capillaries is the most significant factor that affects the drug distribution. Assuming that the concentration of drug in the blood is small compared to that in the tissue and that the drug in the tissue is low enough for any enzymatic reactions, the elimination kinetics can be approximated to follow a firstorder process [22] , [26] . The elimination rate constant of the drug in the tumor can be defined as
where, γ v is the drug loss rate constant due to perfusion through the capillaries (circulatory system), γ e is the drug degradation rate constant due to the enzymatic reaction, and γ o is the drug degradation rate constant due to other nonenzymatic factors. In this paper, we assume the drug loss rate due to lymphatic drainage to be equal to zero, due to a lack of lymphatic system inside the tumors [13] , [34] . The chemical alteration or degradation of drug molecules due to metabolism, such as enzymatic reaction, may convert drug molecules into other inactive substances.
A. CHANNEL IMPULSE RESPONSE
Assuming the tumor to be spherically shaped, Eq. (1) can be expressed in the spherically symmetric coordinate system, as
where C (r, t; r 0 , t 0 ) is the distribution of drug molecules at time t at radial position r from the center of the implant due to release of drug molecules at time t 0 at a radial position r 0 . This distribution represents the final channel impulse response (CIR).
To obtain the CIR, the anticancer drug DOX is instantaneously released at the time t = t 0 at the spatial location r = r 0 from the implant. Thus, the following initial condition is applied:
where r 0 is the implant radius and δ(·) is Dirac Delta function. In this model, two boundaries must be characterized, namely, the inner boundary at the center of the implant and the outer boundary at the tumor surface. Drug concentration is assumed to be finite at the center of the implant. This is applied via the following additional boundary condition:
Robin boundary condition [35] , [36] , is chosen as a general flux boundary condition at the outer surface of the tumor.
where ω is the loss rate at the tumor boundary in the units of m/s. As a special case, by adjusting the loss rate ω, Robin boundary condition can be reduced either to a fully permeable (perfect-sink) case or an impermeable (no-flux) case. The drug distribution at the location r and at the time t due to an instantaneous drug release from a point-like source at the position r = r 0 and at the time t = t 0 inside an unbounded medium can be written following [37] , but only after the inclusion of a general initial releasing time and an elimination rate term as
where, r − r 0 is the separation distance between the drug point source and the observation point.
We assume that the drug molecules are uniformly distributed and released on the implant surface [44] - [46] . Thus, the drug distribution due to instantaneous drug release from the implant can be obtained by integrating Eq. (9) over the implant surface area (A 0 ) after transforming the parameters to the spherical coordinate system, as shown below:
is the polar angle. By transforming Eq. (9) to a spherical coordinate system recognizing that the medium is spherically symmetric (i.e., φ = θ = 0), we get
Substitution of Eq. (11) in (10) results in
Evaluating the integral in Eq. (12) using [38, eq. (3.915.1)], C s can be written as
Now apply the Laplace transform on Eq. (13) which can be evaluated with the help of [39, eq. (29.3.84)] to get C s = e γ t 0 e −st 0 4π r 0 rDζ × e −r 0 ζ sinh (rζ ) , r < r 0 e −rζ sinh (r 0 ζ ) , r > r 0 (14) whereC s is the Laplace transform of C s and
The CIR due to an instantaneous (impulsive) drug release from the implant can be expressed as a superposition of two functions using a mathematical technique similar to that used in [40] , [41] ,
Here, the parameters (r, t; r 0 , t 0 ) are omitted to simplify the mathematical notations. The total solution (16) can be written in the Laplace domain as
where,C is the Laplace transform of C and the multiplication factor r used to simplify the mathematical derivation.
The term C b is the solution of the following diffusion equation which vanishes at t = t 0 and when it is added to C s will satisfy the boundary conditions (7)- (8) .
Converting Eq. (18) into an ordinary differential equation (ODE) using Laplace transform to get
The diffusion equation (19) is a second-order ODE which has two roots at ±ζ . Thus, its solution can be expressed as
After substituting Eqs. (14) and (20) in (17) for the case of r > r 0 , we get
The general solution given by Eq. (21) should satisfy the boundary conditions (7)- (8) in the Laplace domain given bỹ
We can rewrite the boundary condition (23) in an appropriate form to make the derivation mathematically tractable. Thus, using product rule of differentiation, we mathematically manipulate to get ∂ rC
Combining (23) and (24), we get ∂ rC
where,
After applying the boundary conditions (22) and (25) to (21), we obtain the following expressions for A and B as
The CIR is obtained by substituting (27)- (28) in (21) as
The Inverse Laplace transform of (29) can be obtained using Cauchy's residue theorem [42] ,
Res C e st (30) where Res(C) is the residue ofC. The expression (29) has a simple pole at s = −γ with zero residue and an infinite number of simple poles at s = −(Dκ 2 n r 2 t + γ ) for n = 1, 2, . . . , ∞. The parameter κ n gives the real positive roots of the following equation:
Thus, the Inverse Laplace transform of (29) can be written as
At the roots of Eq. (31), we get the following identity
Substituting (33) in (32) after applying Euler's formula on the complex exponentials (e −iκ n ), we get
The equation (34) represents the CIR due to drug release instantaneously from a spherical drug implant following insertion inside an isolated spherical tumor. The equation (34) is an infinite series and has an infinite number of roots. However, this infinite series converges for a finite number of roots while the remaining roots have negligible effect and can be ignored. It must be recognized that the roots of ϕ(κ n ) have a significant impact on the evaluation of Eq. (34) . In order to evaluate (34) with higher accuracy, we have developed an accurate algorithm to find the roots of ϕ(κ n ). The roots that have a negligible contribution to the final result have been discarded.
B. DRUG RELEASE KINETICS
The main design parameter for the implant is the release rate across the polymer surface. The release rates can be adjusted during the design phase by selecting appropriate materials and varying thickness of the polymer coating as well as the physicochemical variable properties of the loaded drug [43] . Moreover, the rate of drug release may also depend on the interactions between the drug and the tissue surrounding the implant as well as on the polymer-drug interaction, which in turn may affect the therapeutic process. In this release kinetic model, we assume that the implant releases DOX over two phases, viz., burst and sustained releases. During the burst release phase, the drug will be released with a fast VOLUME 7, 2019 release rate over a short time followed by slow release over an extended period of time during the sustained release phase. For example, both the in-situ forming implants (ISFIs) [7] , and the double-layer polymer implants [15] have dual release patterns. Thus, the cumulative amount of released DOX at time t can be mathematically modeled using the first-order bi-exponential kinetic model as
where, W (t) is the percentage of cumulative DOX released at time t, and W ∞ is the total percentage of DOX released at steady state. The parameters f 1 and f 2 are the DOX fractions released during the burst and sustained phases, respectively.
The constants k f and k s are the release rate constants of burst and sustained release processes, respectively. We can also obtain a model only for the sustained release implant by just removing the burst release phase, i.e., f 1 = 0 in Eq. (35) .
For an accurate representation of the release rate in the analysis, we use the bi-exponential kinetic model to fit the experimental release data of PLGA implants extracted from [7] . Using the nonlinear least-squares fitting method, we obtain the release rate constants as listed in Table 1 . As shown in Fig. 2 , the fitted curve shows good agreement with the experimental data with R 2 = 0.9956. The cumulative amount of released DOX at time t can be expressed as
where M 0 is the total amount of loaded DOX in the implant in the unit of mg. The drug release profile can be considered spatially uniform from the implant surface [44] - [46] . The drug release rate from the implant at time t can be expressed as
The drug release rate can be approximated as [24] ,
In this model, the size variation of the implant due to polymer biodegradation is assumed to be negligible during the observation time [7] , [47] .
C. DRUG CONCENTRATION PROFILE
Using the linear system analysis technique [ 30] , drug concentration profile at any location inside the tumor can be obtained by applying the convolution between the CIR (34) and the release rate expression (37) . After applying the convolution, we get the following spatiotemporal drug concentration profile,
sin κ n r 0 r t sin κ n r r t κ 2 n + λr t (λr t − 1)
where H (t) is the unit (or Heaviside) step function. By solving the integral in (39) assuming the initial release time t 0 is equal to zero, we get
α n sin κ n r 0 r t sin κ n r r t α n − λr t
III. STOCHASTIC SIMULATION MODEL
Stochastic simulations play an important role in understanding random diffusion and modelling of drug transport and interaction mechanisms. We implement a particle-based stochastic simulator in MATLAB for predicting drug release from a miniature spherical implant and for monitoring drug transport through the surrounding tissue in a spherically bounded 3-D tumor microenvironment. The total simulation time is divided into many small time-steps t. The release process is performed according to experimentally fitted bi-exponential model following insertion of the implant inside the tumor. The amount of the released drug during each time-step, i.e., [t, t + t], can be expressed as
Substituting (35)- (36) in (46), we get
The number of released molecules can be expressed as N 0 M (t, t + t) (M 0 W ∞ ). However, to obtain the CIR using stochastic simulation, all the molecules must be released instantaneously, i.e., at the first-time step. The movement of molecules in the extracellular matrix (ECM) of the tumor depends on the physiochemical properties of both the molecules and the ECM. The ECM is composed of networks of collagen fibers and other cells. Molecules diffuse through the spaces between network structures according to Brownian random walks. This random motion of molecules is influenced by the components of the ECM whose aggregate influence can be represented by using an apparent (or effective) diffusion coefficient (ADC). In the literature, it is common to use ADC to determine the diffusion of drugs in the ECM where ADC is equal to that in the real restricted extracellular matrix [48] . This allows us to use the ADC together with time-step to calculate the spatial displacements of molecules that follow random Brownian motion. Therefore, the released drug molecules will diffuse according to an independent random walk process (Brownian motion) in the simulation environment, i.e., tumor. The new position of each molecule is tracked and stored using the following equation [49] :
where, the index i refers to the current time-step, (x i , y i , z i ) are the coordinates of the current location of drug molecules at i th time-step, (x i−1 , y i−1 , z i−1 ) are the coordinates of the previous location of drug molecules at (i-1) th time-step, and ( x i , y i , z i ) is the random displacements which follow the normal distribution N (0, σ 2 ) with zero mean and variance equal to σ 2 = 2D t. The elimination of drug molecules in the simulation environment due to cellular uptake/binding, perfusion through blood vessels, and degradation are modelled using a firstorder degradation reaction mechanism [22] , [25] . At each time step, a uniformly distributed random number R 1 between zero and one is generated for each molecule. Then, the generated random numbers are compared with the elimination probability in Eq. (49) [50] :
If the elimination probability is larger than the random number R 1 , the molecule will be removed from the simulation environment.
The outer surface of the simulation environment (tumor) is modelled as a general partially reflecting boundary, which is mathematically equivalent to the Robin boundary condition used in our analytical model given in section II. Some of the molecules will be reflected when they reach the boundary and others will be removed from the environment. This condition can represent the effect of DOX elimination to the neighboring tissue or leakage into the exchange blood and lymphatic vessels at the outer boundary of the tumor where many exchange vessels exist that may act as sinks for drug molecules [32] . The partially reflecting boundary condition can be reduced to other special cases, e.g., no-flux (fully reflecting) boundary.
A uniformly distributed random number R 2 , between zero and one, is assigned to each molecule that hits the medium boundary. Then, if the forward reaction probability, given by Eq. (50) , is larger than the random number R 2 , the drug molecule will be removed from the simulation environment [41] :
Otherwise, the drug molecule will reflect back to the previous location inside the environment. The impermeable (no-flux) boundary condition can be used when no molecule transmission takes place at the boundary, i.e., ω = 0. On the other hand, when each collision between molecule and boundary leads to transmission, a fully permeable boundary condition can be applied, i.e., ω → ∞. The interaction of drug molecules with the medium boundary occurs within a short period of time. Therefore, the time step should be small enough for modelling the interaction and permeation of drug molecules at the medium boundary.
The spatiotemporal drug concentration profile inside the simulation environment can be estimated using a virtual spherical observer that does not hinder movements of the molecules. At each time step, the drug molecules that enter the observer volume will contribute to the total received molecules. Then, the drug concentration profile can be obtained as follows (51) where N is the total number of the received molecules, N 0 is the total number of released molecules from the implant, and V rx is the receiver (or observer) volume.
IV. RESULTS
In this section, we will first examine the accuracy of the CIR, given in (34) , which is the basis for deriving the drug concentration profile. Then, we examine the effect of various system parameters on the transport of anticancer drug DOX in terms of the drug concentration profile and the maximum concentration after implantation of the dual-release implant in the tumor. The results are obtained using both the proposed models, viz., analytical model and stochastic particle-based simulator. Also, accuracy of the predicted results by our proposed models is verified by comparing with the published experimental data on DOX bio-distribution in tumor extracted from [19] . The system parameters used in our computations are listed in Tables 1 and 2 . The diffusivity of DOX inside the tumor is chosen to fall within the range of the experimentally measured data published in [14] , [51] . To choose optimal values for the simulation parameters, we first conduct a trial and error run with different values of the time-step and the number of transmitted molecules to examine the concentration profile variations. For example, when the time-step is less than 0.1h, we found no significant change and variation in the simulation results. We chose the tumor radius in our models to be equal to 1 cm. This value falls within the range of different tumor sizes encountered in reality, e.g., the diameter of tumors in rat and rabbit ranges from 0.5 to 2 cm [52] . The radius of the virtual observer (r rx ) is chosen to be 0.5 mm so that enough molecules can contribute to estimating the concentration within the receiver volume. The elimination rate constant (γ ) also has a range of values, and thus different values are chosen for the calculations to examine its effect on the drug distribution profile [14] . In Fig. 3 , we plot the CIR and the drug concentration profile for different values of the elimination rates. The results in this figure indicate a similar trend. The analytical results obtained using the expressions (34) and (40) , match well with the stochastic simulation results. Thus, the agreement of the results obtained from the two independent models demonstrates the validation of the modelling approaches proposed in this paper. As expected, an increase in the elimination rate due to different factors, e.g., vascular perfusion, cellular uptake, enzymatic and non-enzymatic metabolisms, etc., will result in a decrease of the drug concentration in the tumor. The drug metabolisms and drug clearance through the capillaries reduce the amount of the drug in the tissue. Therefore, fast metabolic rate leads to higher biotransformation of drug in the tissue compared to low metabolic rate Moreover, drug concentration increases with the time until reaching the peak concentration and then it decreases gradually to a minimal value. The maximum (or peak) drug concentration C max and the corresponding peak time t max at a specified location in the tissue represent important pharmacokinetic metrics. In this section, these metrics are obtained from the drug concentration profile using the analytical and simulation models presented in the previous sections. Figures 4 and 5 show the maximum drug concentration as a function of the separation distance from the implant center For the simulation model, since the radius of the virtual observer r rx = 0.5 mm, we need to start recording the concentration at a distance 0.5mm from the implant surface (i.e., 1.5 mm from the centre of the implant) to avoid intersection of the virtual observer (receiver) with the implant. The results in this figure are obtained using both the proposed models for various drug elimination rates. Drug concentration decreases as the distance from the implant increases and finally reach zero at the tumor boundary. Moreover, the higher elimination rate will lead to lower maximum drug concentration as shown in Fig. 4 . Also, the effective drug diffusivity has an impact on transport and distribution of drug in the tumor, as shown in Fig. 5 , where the higher diffusivity leads to lower peak concentration. Figure 6 shows the impact of the loss rate at the tumor boundary on the drug concentration profile inside the tumor tissue. Drug concentration decreases as the loss rate increases. This happens because the probability of drug elimination through the boundary will increase with the increase in the loss rate. Adding the loss rate ω to our model via Robin boundary condition allows us to select the appropriate boundary condition at the tumor boundary by adjusting the value of ω, e.g., ω = 0 leads to no-flux at the boundary.
Impact of the sustained release rate on both the maximum drug concentration and the corresponding time instant is plotted versus the separation distance from the implant center in Fig. 7 . As shown in Fig. 7a , the maximum drug concertation increases as the sustained release rate increases because more drug will be released from the implant within a shorter time. Impact of the sustained release rate on the maximum drug concentration decreases as the distance from the implant increases and finally the maximum concentration converges for all the release rates because the distance becomes the main dominant factor. On the other hand, the time at which the concentration is maximum becomes shorter with the increase in sustained release rate as shown in Fig. 7b , since a higher amount of drug will be released within a shorter time.
To verify the accuracy and validity of our proposed models we compare the results predicted by both of our proposed models with the published experimental data extracted from [19] . The experimental data provides measured DOX concentration with the distance from polymer implant placed in a liver tumor. Drug transport from this implant to the surrounding tissue is symmetric around the implant axis due to the geometry of the implant. To compare the results from our models with the measured data on DOX distribution, we use the same diameter of the implant and the tumor as that used in [19] , i.e., 1.6 mm and 1.1cm, respectively. We estimate the implant release rate constant (0.5341 day −1 ) by curve fitting the releasing rate characteristics given in [19] . The amount of loaded DOX in the implant is 2.99 mg and 93.7% of the loaded drug is released on the fourth day, VOLUME 7, 2019 i.e., 2.8 mg. These data are extracted from the experimental data given in literature and are used to compute our results [16] , [19] .
The apparent diffusivity and apparent elimination rate constant of DOX in liver tumor tissue are given as D = 50 µm 2 /s and γ = 0.58 × 10 −4 s −1 respectively [14] . The density of tumor and liver tissues is equal to ∼1.04 g/cm 3 ; therefore volume can be replaced with mass for obtaining the concentration in unit of (µg/g) [53] , [54] . Figure 8 shows a comparison of DOX concentration obtained using our proposed models with the published experimental data as a function of the radial distance from the implant surface on the fourth day after implantation in the tumor. It can be seen that the results obtained using our analytical and stochastic models agree well with the results extracted from the published experimental data in [19] . As expected, the measured concentration shows a decreasing trend with the radial distance from the implant. In general, our proposed models can predict the DOX concentration in the tumor at different radial distances from the implant accurately. Moreover, the experimental data extracted from the literature and plotted in this figure represent the mean values, and the predicted results by our models fall within the standard deviation of the mean.
V. CONCLUSION
In this paper, we have proposed analytical and stochastic simulation models based on molecular communication paradigm for predicting the release and distribution of anticancer drug doxorubicin (DOX) in an isolated tumor following implantation of a dual-release implant. We derive a closed-form analytical expression of DOX concentration profile in the tumor by applying the convolution between the implant release function and the derived channel impulse response (CIR). In addition, we develop a stochastic simulation approach to model the DOX drug release from the implant and for monitoring the distribution of drug molecules in the surrounding tumour tissue. Accuracy and validity of the proposed models can be seen from the comparison with the experimental data given in the literature. Impact of the various parameters on the drug concentration profile and the CIR, i.e., elimination rate, diffusivity, loss rate at the tumor boundary, and the implant release rates, are examined. Also, the analytical and simulation results of the peak time and drug peak concentration are obtained with respect to the radial distance from the centre of the implant. The proposed models can help to optimize the design and deployment of the implantable drug delivery systems (IDDSs) in tumors or any other tissues by adjusting the system parameters. Although we derive the drug concentration profile for the first-order bi-exponential kinetic model, the CIR can be used for modelling other implants that may have different drug release patterns.
